Patents Examined by Louise Humphrey
-
Patent number: 8986712Abstract: The present invention relates to peptides, derivatives and analogs comprising an amino acid sequence derived from the transmembrane domain of HIV gp41 protein, pharmaceutical compositions comprising same, and uses thereof for therapy of inflammatory diseases and disorders, such as T-cell and/or monocyte mediated diseases.Type: GrantFiled: November 29, 2010Date of Patent: March 24, 2015Assignee: Yeda Research and Development Co., Ltd.Inventors: Yechiel Shai, Irun R. Cohen, Tomer Cohen
-
Patent number: 8980634Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.Type: GrantFiled: January 30, 2009Date of Patent: March 17, 2015Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Chaouki Miled, Frédéric Tangy, Yves Jacob
-
Patent number: 8980281Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.Type: GrantFiled: February 12, 2010Date of Patent: March 17, 2015Assignee: Academia SinicaInventors: Pei-Wen Hsiao, Chia-Ying Wu, Yi-Chun Yeh
-
Vectors with modified initiation codon for the translation of AAV-REP78 useful for production of AAV
Patent number: 8952144Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.Type: GrantFiled: July 18, 2013Date of Patent: February 10, 2015Assignee: Uniqure IP B.V.Inventors: Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker -
Patent number: 8945590Abstract: This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.Type: GrantFiled: March 25, 2009Date of Patent: February 3, 2015Assignee: Juvaris BioTherapeutics, Inc.Inventors: Jeffery Fairman, Marla Lay Vaughn
-
Patent number: 8940517Abstract: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.Type: GrantFiled: April 18, 2012Date of Patent: January 27, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Michael Graninger, Martin Kaliwoda
-
Patent number: 8936789Abstract: Provided herein are immunogenic compositions comprising fusion proteins, the fusion proteins comprising lentivirus gp41 or a fragment thereof, a trimerization or oligomerization motif and an immunoenhancer that elicit potent and broad HIV neutralizing antibody responses in the immunized hosts. Also disclosed are methods of making and using the immunogenic compositions.Type: GrantFiled: October 16, 2009Date of Patent: January 20, 2015Assignee: New York Bood Center, Inc.Inventors: Shibo Jiang, Zhi Qi, Chungen Pan
-
Patent number: 8932830Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: January 13, 2015Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Patent number: 8926995Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.Type: GrantFiled: November 23, 2011Date of Patent: January 6, 2015Assignee: Duke UniversityInventors: Barton F. Haynes, Laurent Verkoczy, M. Anthony Moody, Matt T. Holl, Masayuki Kuraoka, Garnett Kelsoe
-
Patent number: 8921050Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: GrantFiled: March 16, 2007Date of Patent: December 30, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Patent number: 8916353Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.Type: GrantFiled: October 20, 2011Date of Patent: December 23, 2014Assignee: Zoetis W LLCInventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
-
Patent number: 8911955Abstract: A virus detection device includes a diffusion unit configured to diffuse a virus in a gas as an inspection target into an aqueous solution containing a fluorescent antibody specifically adsorptive to the virus by bringing the gas into contact with the aqueous solution and configured to adsorb the fluorescent antibody to the virus in the gas; an atomization unit configured to atomize the aqueous solution and generate a mist group of the aqueous solution in which the gas is diffused; a fluorescence measuring unit configured to measure a fluorescence intensity of the mist group; and an air current generator configured to form an air current flowing toward the fluorescence measuring unit from the atomization unit.Type: GrantFiled: April 26, 2013Date of Patent: December 16, 2014Assignee: Tokyo Electron LimitedInventors: Akitake Tamura, Kaoru Fujihara, Misako Saito
-
Patent number: 8911935Abstract: Methods described herein relate to mitochondria and their role in Human immunodeficiency virus type 1 (HIV-1) infection and cell-to-cell HIV-1 transmission and compositions and methods for modulating mitochondrial mediated cell-to-cell transmission of HIV-1. Methods for screening to identify inhibitors of mitochondrial mediated cell-to-cell transmission of HIV-1 are also envisioned herein.Type: GrantFiled: October 17, 2012Date of Patent: December 16, 2014Assignee: New York UniversityInventors: Sylvia Lee-Huang, Paul Huang, Philip Huang
-
Patent number: 8911975Abstract: The present invention discloses a cell system, as a host cell to be infected with an F gene-deficient virus, which can constitutively and stably express the F protein, and a method for producing an F gene-deficient virus by utilizing the cell. A non-proliferative human parainfluenza type 2 virus vector is produced by co-culturing an F gene-deficient human parainfluenza type 2 virus with a Vero cell having the F gene of human parainfluenza type 2 virus in such a manner that the F gene is non-inducibly expressed, and isolating viral particles from a culture supernatant.Type: GrantFiled: February 8, 2012Date of Patent: December 16, 2014Assignees: Mie University, BioComo Inc.Inventors: Masayuki Fukumura, Mitsuo Kawano, Tetsuya Nosaka, Junpei Ohtsuka
-
Patent number: 8906634Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.Type: GrantFiled: March 14, 2013Date of Patent: December 9, 2014Assignee: Institut PasteurInventors: Marie-Lise Gougeon, Hela Saidi, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
-
Patent number: 8900864Abstract: A method of producing extremely stable leukocytes from human blood samples which are stable for long period of time under extraordinary temperature conditions. The method also relates to producing and stabilizing the leukocytes with formaldehyde release agents. The method is directed at the use of the stabilized leukocytes as a control in assays for determining CD4+ and HIV diagnosis and therapy.Type: GrantFiled: September 13, 2011Date of Patent: December 2, 2014Assignee: Nordrhein-Wesfalen Krankenhausbetriebsgesellschaft Bad Oeynhausen mbHInventors: Christian Prante, Knut Kleesiek, Wolfgang Prohaska
-
Patent number: 8900827Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: December 2, 2014Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Patent number: 8903474Abstract: Systems and techniques for the analysis of gases for medical purposes are described. In one aspect, a system includes a sample collector to collect a physical sample associated with an individual and present a gas sample for analysis, a gas analysis device to analyze the gas sample presented by the sample collector to determine a concentration of one or more non-aqueous gases in the gas sample, a data storage device that includes information reflecting a correlation between concentration of the one or more non-aqueous gases in the gas sample and a disease state, and a data analysis device to determine a medical condition of the individual based on the concentration of one or more non-aqueous gases in the gas sample and the information.Type: GrantFiled: December 5, 2006Date of Patent: December 2, 2014Assignee: PEN Inc.Inventors: Zvi Yaniv, Prabhu Soundarrajan
-
Patent number: 8889849Abstract: Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.Type: GrantFiled: July 5, 2012Date of Patent: November 18, 2014Assignee: Gilead Sciences, Inc.Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Betty Peng
-
Patent number: 8889848Abstract: Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.Type: GrantFiled: July 5, 2012Date of Patent: November 18, 2014Assignee: Gilead Sciences, Inc.Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa